Clinical Trial

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes. The second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-09-09; most recent amendment 2025-10-24.
Status change: Not Yet Recruiting → Recruiting 2025-10-24
Trial Details
NCT Number NCT06033703
Lead Sponsor Massachusetts Eye and Ear Infirmary
Conditions Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Enrollment 48 participants
Start Date 2025-01-14
Primary Completion 2026-09 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-28